Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing <i>BCR-ABL1</i> <sup>T315I</sup>-compound mutations.
Karoline V. Gleixner, Yüksel Filik, Daniela Berger, Christina Schewzik, Gabriele Stefanzl, Irina Sadovnik, Lina Degenfeld‐Schonburg, Gregor Eisenwort, Mathias Schneeweiss‐Gleixner, Konstantin Byrgazov, Wolfgang R. Sperr, Jiřı́ Mayer, Thomas Lion, Peter Valent
Abstract
compound mutations and CML stem cells. The clinical efficacy of this TKI combination needs to be evaluated within the frame of upcoming clinical trials.
Topics & Concepts
PonatinibCancer researchMyeloid leukemiaStem cellbreakpoint cluster regionMedicineBiologyDasatinibImatinibInternal medicineCell biologyReceptorChronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia ResearchEosinophilic Disorders and Syndromes